|
Consensus recommendations |
Grade |
|
People with HCV–HIV coinfection should be cared for by a clinician who is experienced in managing both viral infections. |
B1 |
|
All people living with HCV should be tested for HIV. |
A1 |
|
All HCV-negative people living with HIV should be tested for HCV annually if they have risk factors for HCV exposure. |
A1 |
|
HIV should be controlled before HCV treatment. |
B1 |
|
ART should not be switched for people who are on a stable regimen, unless an unavoidable and unmanageable drug–drug interaction is identified. |
B1 |
|
The treatment regimens for chronic HCV infection in people living with HIV should be the same as those used for HCV mono-infection, because DAA regimens for the treatment of HCV are just as effective in the setting of HIV coinfection. |
B1 |
|
A careful assessment of potential drug–drug interactions between DAAs and ART and drugs prescribed to manage HIV-related complications and comorbidities should be performed and used to guide the selection of an appropriate DAA regimen for HCV.. |
A1 |
|
HIV-positive individuals who achieve SVR after DAA therapy and who remain at risk of reinfection with HCV should continue to be screened with annual HCV RNA PCR and 3–6-monthly liver function test monitoring. |
C2 |